Studi scientifici principali

1. Barritt AS 4th, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012 May;142(6):1314-1323.


2. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012 May;19 Suppl 2:1-26.


3. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012 Mardcx-Apr;11(2):179-85.


4. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May;55(5):1620-8.


5. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56 Suppl 1:S88-100.


6. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology. 2012 Apr;55(4):1048-57. doi: 10.1002/hep.24791. Epub 2012 Mar 1.


7. Leise MD, Kim WR, Canterbury KM, Poterucha JJ. Drug therapy: telaprevir. Hepatology. 2011 Oct;54(4):1463-9.


8. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul;54(1):3-5.


9. Zeuzem S, et al. Hepatology 2010;52(Suppl.):436A